Euclises Pharmaceuticals, Inc. Announces CEO Bobby W. Sandage, Jr., Ph.D. to Present at 9th Annual Biotech Showcase on January 9, 2017

ST. LOUIS--()--Euclises Pharmaceuticals, Inc., a privately held drug discovery and development company focused on novel third-generation cyclooxygenase-2 (COX-2) inhibitors for use in the treatment of cancer, today announced that Bobby W. Sandage, Jr., Ph.D., president and chief executive officer, will present an overview of the company and its programs at the 9th Annual Biotech Showcase Conference on Monday, January 9, 2017 at 9:45 a.m. PST. The conference will take place at the Hilton San Francisco Union Square, San Francisco, CA.

About Euclises:

Euclises Pharmaceuticals, Inc., is a drug discovery and development company focused on novel third-generation cyclooxygenase-2 (COX-2) inhibitors for use in the treatment of cancer. These drugs are designed to work in combination with certain other anti-cancer drugs, in particular checkpoint inhibitors (CIs), by preventing COX-2 produced PGE-2 from inhibiting the natural immune cells from killing cancer cells.

COX-2 produced PGE-2 inhibits cytotoxic T-cell function in the tumor microenvironment. Euclises’ lead candidate inhibits COX-2, blocks PGE-2 production and thereby synergizes with CIs, which depend on the activity of the patient’s own immune system to work at peak performance. In preclinical studies, Euclises’ drug candidate has demonstrated the ability to enhance the efficacy of CIs in boosting immune control of tumors. In addition, in a number of tumor types, PGE-2 drives cancer cell proliferation, and Euclises’ lead candidate has been shown non-clinically to be effective in inhibiting tumor growth alone and in combination with other targeted therapies.

Euclises has selected a clinical development candidate and is currently conducting studies in preparation for human clinical trials with the goal of submitting an Investigational New Drug (IND) application to the FDA in the first half of 2017. For more information, visit the Euclises website at www.euclises.com.

Forward-Looking Statements:

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are those involving future events and future results that are based on current expectations, estimates, forecasts and projections as well as the current beliefs and assumptions of the Company’s management. Words such as “outlook,” “believes,” “expects,” “appears,” “may,” “will,” “should,” “anticipates” or the negative thereof or comparable terminology, are intended to identify such forward-looking statements. Any statement that is not a historical fact is a forward-looking statement. Forward-looking statements are only predictions and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore actual results may differ materially and adversely from those expressed in any forward-looking statements. You should not place undue reliance on forward-looking statements. The Company does not assume any obligation to update the information contained in this press release.

Contacts

Euclises Pharmaceuticals, Inc.
Bobby W. Sandage, Jr., Ph.D., 314-932-4032 x317
bsandage@euclises.com

Release Summary

Euclises Pharmaceuticals presenting at 9th Annual BioTech Showcase on novel COX-inhibitors and cancer combination treatment.

Contacts

Euclises Pharmaceuticals, Inc.
Bobby W. Sandage, Jr., Ph.D., 314-932-4032 x317
bsandage@euclises.com